Literature DB >> 17885814

A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression.

Arjuna Kumarasuriyar1, Christian Dombrowski, David A Rider, Victor Nurcombe, Simon M Cool.   

Abstract

Several methods to alter cell surface glycosaminoglycan (GAG) expression have previously been described, including treatments with chlorate to reduce the addition of charged sulfate groups, xyloside compounds to displace GAGs from their core proteins, and GAG lyases, such as heparinase and chondroitinase, to release GAG fragments from the cell layer. While these methods are useful in identifying cellular mechanisms which are dependent on GAGs, they must be stringently validated to assess results in the appropriate context. To determine the most useful technique for the evaluation of GAG function in osteogenesis, MG-63 osteosarcoma cells were systematically treated with these agents and evaluated for changes in cell surface GAGs using a TAT-EGFP fusion protein. TAT, a protein transduction domain from the HIV-1 virus, requires cell surface GAGs to traverse cell membranes. The EGFP component provides a method to assess protein entry into cells in both qualitative and quantitative tests. Here, TAT-EGFP transduction analysis confirmed radiochemical and physiological data that chlorate effectively disrupts GAG expression. TAT-EGFP entry into cells was also inhibited by the exogenous application of commercial heparin and GAGs extracted from MG-63 cells as well as by the pre-treatment of cells with chondroitinase ABC. However, neither heparinase III treatment nor the addition of exogenous chondroitin-6-sulfate affected TAT-EGFP entry into cells. In addition, xyloside-beta-D-naphthol and xyloside-beta-D-cis/trans-decahydro-2-naphthol treatment could not induce significant phenotypic change in these cells, and the unaffected TAT-EGFP transduction confirmed that this was due to an inability to efficiently prime GAG synthesis. The use of TAT-EGFP is thus a useful technique to specifically evaluate cell surface GAG expression in a simple, quantifiable manner, and avoids the complications involved with conventional radiochemical assays or analytical chromatography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17885814     DOI: 10.1007/s10735-007-9136-z

Source DB:  PubMed          Journal:  J Mol Histol        ISSN: 1567-2379            Impact factor:   3.156


  81 in total

1.  Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin.

Authors:  H C de Boer; K T Preissner; B N Bouma; P G de Groot
Journal:  J Biol Chem       Date:  1992-02-05       Impact factor: 5.157

2.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration.

Authors:  H Nagahara; A M Vocero-Akbani; E L Snyder; A Ho; D G Latham; N A Lissy; M Becker-Hapak; S A Ezhevsky; S F Dowdy
Journal:  Nat Med       Date:  1998-12       Impact factor: 53.440

3.  Evidence for the role of proteoglycans in cation-mediated gene transfer.

Authors:  K A Mislick; J D Baldeschwieler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  The effect of beta-D-xylosides on the proliferation and proteoglycan biosynthesis of monoblastic U-937 cells.

Authors:  S O Kolset; K Sakurai; I Ivhed; A Overvatn; S Suzuki
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

Review 5.  Glycomics approach to structure-function relationships of glycosaminoglycans.

Authors:  Ram Sasisekharan; Rahul Raman; Vikas Prabhakar
Journal:  Annu Rev Biomed Eng       Date:  2006       Impact factor: 9.590

6.  Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from beta-D-xyloside inhibition of proliferation.

Authors:  S Potter-Perigo; K R Braun; E Schönherr; T N Wight
Journal:  Arch Biochem Biophys       Date:  1992-08-15       Impact factor: 4.013

7.  Chondroitin sulfate in palatal wound healing.

Authors:  X H Zou; W C Foong; T Cao; B H Bay; H W Ouyang; G W Yip
Journal:  J Dent Res       Date:  2004-11       Impact factor: 6.116

Review 8.  Herpes simplex virus: discovering the link between heparan sulphate and hereditary bone tumours.

Authors:  C McCormick; G Duncan; F Tufaro
Journal:  Rev Med Virol       Date:  2000 Nov-Dec       Impact factor: 6.989

9.  Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans.

Authors:  Sandra Console; Cornelia Marty; Carlos García-Echeverría; Reto Schwendener; Kurt Ballmer-Hofer
Journal:  J Biol Chem       Date:  2003-06-30       Impact factor: 5.157

10.  Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization.

Authors:  Lovisa Hessle; Kristen A Johnson; H Clarke Anderson; Sonoko Narisawa; Adnan Sali; James W Goding; Robert Terkeltaub; José Luis Millan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-24       Impact factor: 11.205

View more
  4 in total

Review 1.  Control of cell fate decisions.

Authors:  Simon M Cool
Journal:  J Mol Histol       Date:  2007-10-24       Impact factor: 2.611

2.  An unusual cell penetrating peptide identified using a plasmid display-based functional selection platform.

Authors:  Shan Gao; Melissa J Simon; Christopher D Hue; Barclay Morrison; Scott Banta
Journal:  ACS Chem Biol       Date:  2011-02-22       Impact factor: 5.100

3.  Modulation of Glycosaminoglycans Affects PrPSc Metabolism but Does Not Block PrPSc Uptake.

Authors:  Hanna Wolf; Andrea Graßmann; Romina Bester; André Hossinger; Christoph Möhl; Lydia Paulsen; Martin H Groschup; Hermann Schätzl; Ina Vorberg
Journal:  J Virol       Date:  2015-07-22       Impact factor: 5.103

4.  TAT-mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expression.

Authors:  Melissa J Simon; Shan Gao; Woo Hyeun Kang; Scott Banta; Barclay Morrison
Journal:  Biotechnol Bioeng       Date:  2009-09-01       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.